Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CD 14 antagonist antibodies for treating neurodegenerative diseases

a neurodegenerative disease and anti-cd14 technology, applied in the field of anti-cd14 antagonists, can solve the problems of neurodegeneration death, adverse impact on the quality of life, early death, etc., and achieve the effects of reducing the risk of neurodegeneration death, and reducing the risk of neurodegeneration

Inactive Publication Date: 2020-05-14
IMPLICIT BIOSCI LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about using a medication that blocks a protein called CD14 to treat inflammation in patients with neurodegenerative diseases. This treatment can help to reduce the development or progression of the disease and its symptoms in the central nervous system (CNS) as well.

Problems solved by technology

Neurodegenerative diseases are highly debilitating conditions characterized by a progressive loss of structure and function of neurons, ultimately leading to death of neurons, which have an adverse impact on the quality of life and ultimately lead to early death.
As the population becomes older, the palliative care required for patients suffering from neurodegenerative disorders is becoming a significant health cost to the community.
Whilst significant research to find cures for these debilitating conditions is ongoing, it is likely to be decades before successful treatments to reverse or prevent the effects of neurodegeneration are found.
Patients typically present with progressive muscle atrophy, paralysis, spasticity, and hyperreflexia and this ultimately leads to death through failure of the respiratory muscles (Zhao W., et al.
Treatment options for MND are severely limited.
Both have limited efficacy, extending patient survival for 3-4 months without improving quality of life.
Despite showing several positive effects in relation to amyotrophic lateral sclerosis (ALS) symptoms in clinical trials (the most common form of MND), in the company's own words, the drug does not itself present a “cure”.
The disconnect between muscle and neurons leads to respiratory failure after about 40 months.
There is degeneration of the upper and lower motor neurones leading to muscle weakening and atrophy due to inability for the muscles to function.
Whilst generally cognitive function is spared, the muscle atrophy is sufficient to significantly reduce a patient's quality of life.
However, one of the difficulties in developing treatments for neurodegenerative disorders is the issue of delivery of drugs to the target site across the blood brain barrier (BBB) into the CNS.
This limits the efficiency of drugs targeted to brain diseases and makes it challenging to use biologic medicines for diseases of the brain.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD 14 antagonist antibodies for treating neurodegenerative diseases
  • CD 14 antagonist antibodies for treating neurodegenerative diseases
  • CD 14 antagonist antibodies for treating neurodegenerative diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

Treatment and Prophylaxis of Patients with MND by Systemically Administering Monoclonal Antibody IC14

Experimental Design

[0163]10 patients with familial or sporadic MND (defined as clinically possible, probable, or definite by Awaji-Shima Consensus Recommendations), who exhibited their first symptoms of MND within 3 years of informed consent and who are aged between 18 and 75 years, will be recruited.

Dosage Regimen

[0164]Patients will be assigned to receive one of two dose regimens of IC14 in an unblinded manner: all doses will be delivered IV as an infusion over a 2-hour period:[0165]For the initial 3 patients: IC14 at a dosage of 2 mg / kg on Study Day 1, then 1 mg / kg once daily on Study Days 3-5 for 4 total doses.[0166]For the subsequent 7 patients: IC14 at a dosage of 4 mg / kg on Study Day 1, then 2 mg / kg once daily on Study Days 2-4 for 4 total doses.

[0167]Study participation will continue until 28 days after the last dose of study drug.

Dosage Form

[0168]Sterile glass vial containing...

example 2

IC14 Inhibition of TDP-43-Driven Activation of Primary Human Microglial Cells

[0189]Immune responses in the brain and spinal cord are primarily mediated by microglia which act as a first line of defense and play a key role in initiating and sustaining neuro-inflammatory responses driving neurodegenerative diseases, including ALS (Salter & Stevens (2017) Nat. Med. 23, 1018-1027).

[0190]SOD1 and TDP-43 are intracellular proteins that have been implicated in ALS. In vitro systems using mouse microglia have demonstrated that both proteins are able to act as Damage-Associated Molecular Patterns (DAMPS), activating microglial cells, inducing pro-inflammatory cytokines and promoting neurotoxicity. These responses utilize TLR and NLRP3 signaling, with DAMP-driven activation is inhibited by blocking antibodies to TLR2, TLR4 or CD14 (Zhao et al. (2010) Glia 58, 231-243; and Zhao et al. (2015) Exp. Neurol. 273, 24-35), pointing to a role for the blockade of CD14 in the inhibition of neuroinflamm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
Tmaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

This invention relates generally to agents and methods for treating the development or progression of a neurodegenerative disease. In particular, the present invention relates to CD14 antagonists for use in treating the development or progression of a neurodegenerative disease, including Motor Neurone Disease (MND) and Dementia disease or associated symptoms. The present invention further provides compositions including such agents.

Description

RELATED APPLICATIONS[0001]This application claims priority to Australian Provisional Application No. 2017901462 entitled “Agents for treating or preventing motor neurone disease and uses therefor” filed 21 Apr. 2017 and Australian Provisional Application No. 2018900762 entitled “Agents for treating disease and uses therefor” filed 8 Mar. 2018, the contents of which are incorporated herein by reference in their entirety.FIELD OF THE INVENTION[0002]This invention relates generally to agents and methods for treating the development or progression of a neurodegenerative disease. In particular, the present invention relates to CD14 antagonists for use in treating the development or progression of a neurodegenerative disease, including Motor Neurone Disease (MND) and Dementia disease or associated symptoms. The present invention further provides compositions including such agents.BACKGROUND OF THE INVENTION[0003]Neurodegenerative diseases are highly debilitating conditions characterized b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/28A61P25/02A61P25/28
CPCC07K2317/515A61K45/06A61K38/00A61P25/02C07K16/2896C07K2317/565C07K2317/51C07K2317/70C07K2317/24A61P25/28A61K2039/505A61K2039/545
Inventor REDLICH, GARRY LLEWELLYN
Owner IMPLICIT BIOSCI LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com